

ABOUT THE PROJECT

The **PREVENTABLE Project** aims to assess the clinical, social, and financial impact of applying multidisciplinary and specialised care to prevent advanced disease in families suffering from Rare Tumour Risk Syndromes (RTRS).

WHAT ARE RTRS?


RTRS are hereditary rare diseases responsible for the onset of multiple types of cancer. RTRS patients have a lifetime risk of up to 100% of developing cancer and a 50% chance of transmitting the disease to their offspring.

OBJECTIVES

- Assess and validate the best pathways of care for RTRS;
- Compare the healthcare costs of prevention versus treatment for RTRS;
- Create methods and models to predict RTRS development, outcomes, and healthcare costs;
- Study the receptivity towards (new) pathways of care for RTRS;
- Raise awareness about RTRS for the public, at-risk individuals, healthcare professionals, and policymakers.

WHY SHOULD HEALTHCARE COMPANIES AND ENTREPRENEURS BE INVOLVED?

- To gain valuable insights into the future trends in RTRS management;
- To get first-hand access to new evidence from healthcare, economics, and social sciences regarding RTRS-related research;
- To collaborate with healthcare systems regarding RTRS research, diagnosis, screening technologies and therapies;
- To get first-hand access to new approaches and tools to estimate real health costs of prevention versus treatment for each RTRS syndrome.



OVERVIEW

Duration: **Jan 2023 – Dec 2025**

Planned budget: **4.6 Mio €**

European countries: **9**

Institutions: **16**

CONTACTS: PROJECT COORDINATOR: CARLA OLIVEIRA (I3S) | PREVENTABLE@I3S.UP.PT